文献库搜索 | GeneLibs

Zhai(M),Hu(G),Shen(G),Zhong(Y),Huang(J),Li... iScience 2026-07-17

...mOS) (20.6 vs. 16.6 months; HR 0.73, 95% CI 0.43-1.27; p = 0.267). Additionally, continuing TTFields into the adjuvant p...

Nguyen(J),Reding(KW),B D'Agostino(R),O'Con... Am J Lifestyle Med 2026-06-29

...MOS Social Support survey, respectively, at baseline and 3 months. Linear regression examined associations between socia...

Gaballa(MR),Julian(K),Afrough(A),Hansen(DK... Blood Adv 2026-09-08

...mOS values of 8.1 and 3.6 months, respectively (P = .007, P = .023). In active PCL, Tal LOT achieved mPFS/mOS of 6.9/12....

Xu(XQ),Li(WM),Shi(LC),Wang(H),Li(S),Huang(... BMC Cancer 2026-07-02

...mOS: not reached vs. 20.2 months, p < 0.001; not reached vs. 20.2 months, p < 0.001; and not reached vs. 22.8 months, p ...

Nodbrant(P),Ulff(E),Lagerlund(M),Ellegård(... Acta Oncol 2026-07-03

...mOS is particularly short in PS 3 patients, suggesting to refrain from treatment. mOS is shorter in PS 2 patients than i...

Koumpis(E),Minga(E),Talimtzi(P),Angelopoul... Ann Hematol 2026-07-03

...most common hematological malignancy was myelodysplastic neoplasms and the most common solid tumors included lung, skin,...

Broadbent(C),Kadaba Sridhar(S),Eastman(A),... World Neurosurg 2026-07-03

...mos,CI: [2.5,40], P = 0.030) compared to CAs ≤74° (low-CA). The shunted high-CA subgroup additionally demonstrated a 10-...

Zhang(Z),Feng(L),Zhang(B),Wang(Z),Hu(Z),Zh... Front Nutr None

...MOS) against heat stress-induced injury. The underlying mechanisms of each supplement were also systematically investiga...

Nisa(FU),Ali(M),Khan(T),Lohana(M),Asif(A),... J Egypt Natl Canc Inst 2026-07-06

...mOS 12.9 vs. 11.3 months; HR 0.76) and KEYNOTE-966 (mOS 12.7 vs. 10.9 months; HR 0.83). Triplet regimens (chemotherapy +...

Furman(O),Falah(E),Dvir(I),Satra-Shenes(O)... Neurooncol Adv None

...mOS) was longest with CRT (14 months), compared to 8 months for TMZ and RT monotherapies and 2 months for best supportiv...